Table 1.
Clinical trials concerning nanoparticles in kidney diseases downloaded from the ClinicalTrials.gov database (https://clinicaltrials.gov/, accessed on 30 September 2021).
| NCT Number |
Title | Condition | Actual Enrolment 1 |
Recruitment Status | Location | Age of Participants 2 |
|---|---|---|---|---|---|---|
| NCT05045872 | The Accuracy and Safety of Renal Artery Contrast-enhanced Magnetic Resonance Imaging with Polysaccharide Superparamagnetic Iron Oxide Nanoparticle | Chronic Kidney Diseases | 40 3 | Not yet recruiting |
China | Adult, Older Adult |
| NCT04277377 | Nanoparticle for DSA Removal | Kidney Failure, Presence of Donor Specific Antibodies |
100 3 | Not yet recruiting |
Switzerland | Adult, Older Adult |
| NCT02646319 | Nanoparticle Albumin-Bound Rapamycin in Treating Patients with Advanced Cancer with mTOR Mutations | Advanced Cancers 4 |
2 | Completed | United States | Adult, Older Adult |
| NCT04260360 | Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma | Renal Cell Carcinoma, Kidney Cancer, Adenocarcinoma of Kidney, Adenocarcinoma, Renal, Renal Cell Cancer |
0 | Withdrawn (Not initiated) | No data | Adult, Older Adult |
| NCT02006108 | Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance | Renal Transplant Rejection | 21 | Completed | United States | Child, Adult |
| NCT03961698 | Evaluation of IPI-549 Combined with Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (MARIO-3) | Breast Cancer, Renal Cell Carcinoma |
90 3 | Recruiting | United States | Adult, Older Adult |
| NCT00499291 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Advanced or Refractory Solid Tumors | Cancer | 0 | Withdrawn | No data | Adult, Older Adult |
| NCT02626663 | The Role of Microparticles as a Biomarker |
Atypical Haemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura, Microparticles, Microangiopathic Haemolytic Anaemia |
0 | Withdrawn (PI left the University, sponsor pulled funding) |
United States | Adult, Older Adult |
| NCT03678883 | 9-ING-41 in Patients with Advanced Cancers |
Human malignancies 5 |
350 3 | Recruiting | United States, Netherlands, Spain |
Adult, Older Adult |
| NCT00689065 | Safety Study of CALAA-01 to Treat Solid Tumor Cancers | Cancer, Solid Tumour |
24 | Terminated | United States | Adult, Older Adult |
1 Number of participants. 2 Child—birth-17 years old; adult—18–64 years old; older adult—more than 65 years old; 3 Estimated Enrolment; 4 Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma Recurrent Cervical Carcinoma Recurrent Head and Neck Carcinoma Recurrent Malignant Neoplasm Recurrent Ovarian Carcinoma Recurrent Prostate Carcinoma Recurrent Renal Cell Carcinoma Solid Neoplasm Stage III Bladder Cancer Stage III Prostate Cancer Stage III Renal Cell Cancer Stage IIIA Breast Cancer Stage IIIA Cervical Cancer Stage IIIA Ovarian Cancer Stage IIIB Breast Cancer Stage IIIB Cervical Cancer Stage IIIB Ovarian Cancer Stage IIIC Breast Cancer Stage IIIC Ovarian Cancer Stage IV Breast Cancer Stage IV Ovarian Cancer Stage IV Prostate Cancer Stage IV Renal Cell Cancer Stage IVA Bladder Cancer Stage IVA Cervical Cancer Stage IVB Bladder Cancer Stage IVB Cervical Cancer; 5 Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms, Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukaemia Lymphoma.